Mahmood, H., Al-Khafaji, K. (2000). Immunohistochemical Expression of Carbonic Anhydrase IX and PAX8 in Renal Cell Carcinoma: A Clinicopathological Correlation Study. , 22(3), 360-367. doi: 10.52573/ipmj.2000.182676
Hanan Shukur Mahmood; Khitam Razzak Kadhim Al-Khafaji. "Immunohistochemical Expression of Carbonic Anhydrase IX and PAX8 in Renal Cell Carcinoma: A Clinicopathological Correlation Study". , 22, 3, 2000, 360-367. doi: 10.52573/ipmj.2000.182676
Mahmood, H., Al-Khafaji, K. (2000). 'Immunohistochemical Expression of Carbonic Anhydrase IX and PAX8 in Renal Cell Carcinoma: A Clinicopathological Correlation Study', , 22(3), pp. 360-367. doi: 10.52573/ipmj.2000.182676
Mahmood, H., Al-Khafaji, K. Immunohistochemical Expression of Carbonic Anhydrase IX and PAX8 in Renal Cell Carcinoma: A Clinicopathological Correlation Study. , 2000; 22(3): 360-367. doi: 10.52573/ipmj.2000.182676

Immunohistochemical Expression of Carbonic Anhydrase IX and PAX8 in Renal Cell Carcinoma: A Clinicopathological Correlation Study

Iraqi Postgraduate Medical Journal
Volume 22, Issue 3, July 2023, Pages 360-367    PDF (1.34 M)
Document Type: Research Paper
DOI: 10.52573/ipmj.2000.182676
Authors
Hanan Shukur Mahmood* ; Khitam Razzak Kadhim Al-Khafaji
Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq .
Abstract
ABSTRACT:
BACKGROUND:
Renal cell carcinoma is the third most common cancer of genitourinary tract and account for approximately 2-3% of all cancer death. Conventional clear cell carcinoma comprises 75% of all renal cell carcinoma. Immunohistochemical had greatly improved the diagnostic accuracy of renal cell carcinoma.
AIM OF STUDY:
Evaluation of the expression of  PAX-8 & Carbonic anhydrase IX in randomly selected samples from Iraqi patients who have RCC and correlate their expression with the clinicopathological variables.
PATIENTS &METHODS:
This is a retrospective study of 40 patients who were diagnosed to have renal cell carcinoma, CAIX & PAX-8 markers to be applied to the tumor tissue sections.
The results will be evaluated & correlated with the tumor grade, stage & other clinicopathological features.
RESULTS:
The present study showed that twenty five of cases(62.5%) were conventional clear cell RCC while fifteen of cases (37.5%) were non clear cell RCC. Five of cases (12.5%) were grade 1, twenty three of cases (57.5%) were grade 2, ten of cases (25%) were grade 3 and two of cases (5%) were grade 4. Eighteen of cases (45%) were stage I, seven of cases (17.5%) were stage II and fifteen of cases (37.5%) were stage III. The high expression of CAIX was presented in 71.0% of cases while the low expression was presented in 29.0% of cases, While the PAX-8 expression showed 22.5% of cases were score 0, 20% of cases were score 1, 25% of cases were score 2 and 32.5% of cases were score 3.
CONCLUSION:
Higher expression level of CAIX and PAX-8 in clear cell RCC than in non-clear cell type RCC so aid  in differential diagnosis of RCC subtypes. PAX-8 expression was decreases with high nuclear grade while decrease CAIX levels are independently associated with advanced stage. There was no significant correlation between pax-8 &CAIX and clinicopathological variables as age and sex.
 
 
Keywords
Carbonic Anhydrase IX; PAX8 expression
References
  1. Eble JN et al. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004.
  2. Mulders PF et al. Guideline 'Renal cell carcinoma'.  2008;152 :376–80.
  3. Raspollini MR, Montagnani I, Montironi R, et A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: a report based on 624 consecutive tumors from a single tertiary center.  Pathol Res  Pract. 2017;213:804-8.
  4. Chaan S. Ng et al. Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance. American Journal of Roentgenology. 2008;191:1220-32.
  5. Capitanio U, et al. "The epidemiology of renal cell carcinoma". Eur. Urol.2019;75:85–87.
  6. Maher ER. Hereditary Renal cell carcinoma syndromes: diagnosis, surveillance, management. world J Urol.2018;36:1891-98.
  7. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumors of the urinary system& male genital organs. 4th Lyons,france:IARC; WHO classification of tumor 2016; 8:14-43.
  8. Charles Patrick davis. American Cancer Society. Kidney Cancer (adult)-Renal Cell Carcinoma.2016;10:23-27.
  9. Genega, Musie Ghebremichael and Sabina Signoretti. Carbonic anhydrase IX expression in Renal Neoplasms: Correlation with tumor Type and Grade.2010;134:873-79.
  10. Meaghan L Barr, Lucia B Jilaveanu, et al. PAX-8 expression in renal tumor &distant sites:a useful marker of primary &metastatic renal cell carcinoma.2015;68:12-17.
  11. .Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor PAX2 protein and transmembrane enzyme complex Carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg pathology.2009;33:241-47.
  1. Atkins M, Regan M, McDermott D, et al .Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res.2005;11:3714-21.
  2. Kroeger N, Seligson DB, Klatte T, et al. Clinical, Molecular and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.Eur Urol 2012;61:888-95.
  3. Sangio AR, et al. The use of immunohistochemistry in the diagnostic of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2.hKIM-1,RCCma and CD10.2012;19:128-36 .
  4. Tac ha D,Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic renal tissues: acomprehensive immunohistochemical study App 1 Immunohistochem MoL Morpho.2011;19:293-99.
  5. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumor. AM J surg pathol.2011;35:816-26.
  6. Ashely Cimino-Mathers, Rajni sharma and George J.Netto. Diagnostic use of PAX8, CAIX ,TTF-1 AND TGB in metastatic RCC of the thyroid.Am j Surg pathol. 2011;35:757-61.
  7. Wenjuan Yu, Yuewei Wang, Yanxia Jiang ,Wei Zang and XujunLi. Distinct immunophenotypes and prognostic factors in RCC with sarcomatoid differentiation: a systemic study of 19 immunohistochemical markers in 42 cases. BMC cancer.2017;17:293-99.
Statistics
Article View: 274
PDF Download: 148


Journal Management System. Powered by iJournalPro.com